Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER alphaWTand ER alphaMUTBreast Cancer.Puyang, X., Furman, C., Zheng, G.Z., Wu, Z.J., Banka, D., Aithal, K., Agoulnik, S., Bolduc, D.M., Buonamici, S., Caleb, B., Das, S., Eckley, S., Fekkes, P., Hao, M.H., Hart, A., Houtman, R., Irwin, S., Joshi, J.J., Karr, C., Kim, A., Kumar, N., Kumar, P., Kuznetsov, G., Lai, W.G., Larsen, N., Mackenzie, C., Martin, L.A., Melchers, D., Moriarty, A., Nguyen, T.V., Norris, J., O'Shea, M., Pancholi, S., Prajapati, S., Rajagopalan, S., Reynolds, D.J., Rimkunas, V., Rioux, N., Ribas, R., Siu, A., Sivakumar, S., Subramanian, V., Thomas, M., Vaillancourt, F.H., Wang, J., Wardell, S., Wick, M.J., Yao, S., Yu, L., Warmuth, M., Smith, P.G., Zhu, P., Korpal, M.
(2018) Cancer Discov 8: 1176-1193
- PubMed: 29991605
- DOI: 10.1158/2159-8290.CD-17-1229
- Primary Citation of Related Structures:
- PubMed Abstract:
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant br ...
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant breast cancer metastases continue to be dependent on ERα signaling, there remains a critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). In vitro comparisons of H3B-5942 with standard-of-care (SoC) and experimental agents confirmed increased antagonist activity across a panel of ERα WT and ERα MUT cell lines. In vivo , H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERα WT and ERα Y537S breast cancer that was superior to fulvestrant. Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERα WT and ERα MUT cell lines and/or tumor models. In summary, H3B-5942 belongs to a class of orally available ERα covalent antagonists with an improved profile over SoCs. Significance: Nearly 30% of endocrine therapy-resistant breast cancer metastases harbor constitutively activating mutations in ERα. SERCA H3B-5942 engages C530 of both ERα WT and ERα MUT , promotes a unique antagonist conformation, and demonstrates improved in vitro and in vivo activity over SoC agents. Importantly, single-agent efficacy can be further enhanced by combining with CDK4/6 or mTOR inhibitors. Cancer Discov; 8(9); 1176-93. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1047 .
H3 Biomedicine, Inc., Cambridge, Massachusetts. Manav_Korpal@h3biomedicine.com Ping_Zhu@h3biomedicine.com.,H3 Biomedicine, Inc., Cambridge, Massachusetts.,Breast Cancer Now, Toby Robins Research Centre, The Institute of Cancer Research, London, UK.,START, Preclinical Research, San Antonio, Texas.,Duke University, Durham, North Carolina.,Eisai Inc., Andover, Massachusetts.,PamGene International, Den Bosch, the Netherlands.,Aurigene Discovery Technologies Ltd., Bangalore, Karnataka, India.